公开(公告)号：EP1772452A3

公开(公告)日：2007-07-04

申请号：EP06076915.5

申请日：2001-02-15

申请人： Bristol-Myers Squibb Pharma Company

发明人： Decicco, Carl P. ,  Nelson, David J. ,  Barrett, John A. ,  Carpenter, Alan P. ,  Duran, James J. ,  Rajopadhye, Milind

IPC分类号： C07D413/12 ,  C07D267/00 ,  C07D401/12 ,  C07D401/14 ,  C07F9/09 ,  A61K31/395 ,  A61K31/4427 ,  A61K31/661 ,  A61K51/04 ,  A61P35/00 ,  A61P29/00

CPC分类号： A61K49/14 ,  A61K49/0002 ,  A61K49/085 ,  A61K49/10 ,  A61K51/088 ,  C07D207/26 ,  C07D213/82 ,  C07D267/00 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07F9/6527

摘要： The present invention describes novel compounds comprising: 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in treatment of diseases associated with MMPs.

公开(公告)号：EP1772452A2

公开(公告)日：2007-04-11

申请号：EP06076915.5

申请日：2001-02-15

申请人： Bristol-Myers Squibb Pharma Company

发明人： Decicco, Carl P. ,  Nelson, David J. ,  Barrett, John A. ,  Carpenter, Alan P. ,  Duran, James J. ,  Rajopadhye, Milind

IPC分类号： C07D401/12 ,  C07D413/12 ,  C07D267/00 ,  C07D401/14 ,  C07F9/09 ,  A61K31/395 ,  A61K31/4427 ,  A61K31/661 ,  A61K51/04

CPC分类号： A61K49/14 ,  A61K49/0002 ,  A61K49/085 ,  A61K49/10 ,  A61K51/088 ,  C07D207/26 ,  C07D213/82 ,  C07D267/00 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07F9/6527

摘要： The present invention describes novel compounds comprising: 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in treatment of diseases associated with MMPs.

摘要翻译： 本发明描述了新颖化合物，其包含：1-10个靶向部分; 螯合剂（Ch）; 和靶向部分和螯合剂之间的0-1个连接基团（Ln）; 其中靶向部分是基质金属蛋白酶抑制剂; 并且其中所述螯合剂能够结合至细胞毒性放射性同位素。 本发明还提供本发明化合物，试剂盒及其在治疗与MMP相关的疾病中的用途的新型组合物。